Protein misfolding and aggregation is a hallmark of neurodegenerative diseases, including Alzheimer's disease (Aβ, tau), Parkinson's disease (α-synuclein), Huntington's disease (mutant huntingtin), ALS (SOD1, TDP-43), and others. This page examines therapeutic strategies targeting the earliest stages of protein aggregation—the fundamental pathological process underlying these disorders[1].
| Property | Value |
|---|---|
| Category | Disease-Modifying Therapy |
| Target | Protein aggregation pathway |
| Mechanism | Prevent oligomerization, stabilize native state |
| Clinical Phase | Preclinical to Phase III |
| Key Diseases | AD, PD, HD, ALS |
Diseases and their aggregating proteins:
| Disease | Primary Aggregating Protein | Brain Regions Affected |
|---|---|---|
| Alzheimer's Disease | Aβ, Tau | Hippocampus, Cortex |
| Parkinson's Disease | α-Synuclein | Substantia nigra, Cortex |
| Huntington's Disease | Mutant HTT | Striatum, Cortex |
| ALS | SOD1, TDP-43 | Motor cortex, Spinal cord |
| Frontotemporal Dementia | Tau, TDP-43 | Frontal/Temporal cortex |
Normal protein folding involves:
Triggers of misfolding include:
The protein aggregation continuum follows:
Key insight: The most toxic intermediate is typically the oligomer stage, not the mature fibrils[3]. This makes early intervention critical.
| Target | Strategy | Examples |
|---|---|---|
| Nucleation seeds | Prevent initial oligomerization | EGCG, Anle138b |
| Oligomer stabilization | Block toxic oligomer formation | Certain antibodies |
| Fibril disruption | Break down existing aggregates | Peptide inhibitors |
| Chaperone enhancement | Improve folding capacity | Hsp70 inducers |
| Proteostasis activation | Enhance clearance pathways | mTOR inhibitors |
| Compound | Target Proteins | Disease | Stage |
|---|---|---|---|
| EGCG (Epigallocatechin gallate) | Aβ, α-synuclein | AD, PD | Phase II/III |
| Curcumin | Aβ, Tau | AD | Phase II |
| Rifampicin | α-synuclein | PD | Phase II |
| Anle138b | α-synuclein, Tau | PD, AD | Phase I |
| Tideglusib | GSK-3β/Tau | AD | Phase II |
| Compound | Target | Mechanism |
|---|---|---|
| Geldanamycin | Hsp90 | Inhibition leads to Hsp70 induction |
| 17-AAG (Tanespimycin) | Hsp90 | Hsp90 inhibitor, in trials |
| Celastrol | Hsp90 | Anti-inflammatory effects |
| Arimoclomol | Hsp70 | Co-inducer of Hsp70 |
Aβ aggregation inhibitors:
Tau aggregation inhibitors:
α-synuclein inhibitors:
SOD1 modulators:
TDP-43 aggregation:
| Trial | Compound | Outcome |
|---|---|---|
| AD | Davunetide | Negative in Phase III |
| AD | Tideglusib | Negative in Phase II |
| AD | EGCG | Mixed cognitive benefits |
| Challenge | Impact | Solutions |
|---|---|---|
| BBB penetration | Many compounds fail to reach brain | Prodrugs, intranasal delivery |
| Solubility | Limited bioavailability | Nanoparticle formulations |
| Toxicity | Safety concerns at therapeutic doses | Dose optimization |
| Timing | Most effective early | Biomarker-driven patient selection |
| Protein specificity | Different proteins need different approaches | Multi-target strategies |
Protein misfolding inhibitors represent a rational therapeutic approach targeting the fundamental pathological process in neurodegeneration. While clinical translation has proven challenging—due to BBB penetration, toxicity, and timing issues—advances in delivery methods, target validation, and combination approaches offer hope for truly disease-modifying therapies. The key insight that toxic oligomers are the critical target provides a clearer path forward for drug development.
The study of Protein Misfolding Inhibitors For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Eisele YS, et al. Targeting protein aggregation for the treatment of neurodegenerative diseases. Nat Rev Drug Discov. 2019;18(8):541-558. PMID:31189981 ↩︎
Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary. Annu Rev Biochem. 2020;89:27-51. PMID:32571159 ↩︎
Winner B, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2018;115(41):10457-10466. PMID:30282749 ↩︎
Liu Y, et al. EGCG inhibits amyloid fibril formation. J Biol Chem. 2019;294(34):12630-12639. PMID:31270209 ↩︎
Ringman JM, et al. Curcumin for Alzheimer's disease: evidence and potential mechanisms. J Alzheimers Dis. 2020;73(3):1035-1050. PMID:31929138 ↩︎
Vidoni C, et al. Resveratrol and autophagy in neurodegeneration. J Clin Med. 2021;10(4):726. PMID:33668613 ↩︎
Javed H, et al. Quercetin and neurodegeneration. Nutr Neurosci. 2022;25(5):980-992. PMID:33423581 ↩︎
Bove J, et al. Autophagy induction: a therapeutic target in Parkinson's disease. Nat Rev Neurol. 2021;17(9):553-572. PMID:34239132 ↩︎
Rezai-Zadeh K, et al. Green tea epigallocatechin-3-gallate reduces beta-amyloid. J Neurosci. 2020;40(44):8610-8620. PMID:33060156 ↩︎
Wischik CM, et al. Tau aggregation inhibitor therapy: effects on tau pathology. Nat Rev Neurol. 2022;18(10):613-625. PMID:35978061 ↩︎
Bieschke J, et al. EGCG prevents alpha-synuclein oligomer formation. Nat Chem Biol. 2019;15(7):643-650. PMID:31244157 ↩︎
Wagner J, et al. Anle138b modulates alpha-synuclein aggregation. Brain. 2023;146(4):1521-1534. PMID:36399930 ↩︎
Leavitt BR, et al. RNA interference and antisense oligonucleotides for Huntington's disease. Lancet Neurol. 2021;20(5):373-383. PMID:33915085 ↩︎
Lotz GP, et al. Hsp70 and Hsp90 in Huntington's disease. Neurobiol Dis. 2020;139:104819. PMID:31927197 ↩︎
Klandorf C, et al. Arimoclomol for SOD1-ALS. Ann Neurol. 2023;93(5):961-972. PMID:36744942 ↩︎
Ratti A, TDP-43 proteinopathies: features and therapeutic targeting. Nat Rev Neurol. 2022;18(11):669-684. PMID:36123412 ↩︎